Senhwa Biosciences Inc (6492) Stock Price & Analysis
6492 Stock Chart & Stats
- Day’s Range
- TWD 27.05 - TWD 29.45
- 52-Week Range
- TWD 27.05 - TWD 64.52
- Previous Close
- TWD 29.25
- Volume
- N/A
- Average Volume (3M)
- 141.01K
- Market Cap
- TWD 3.32B
- Enterprise Value
- TWD 3.18B
- Total Cash (Recent Filing)
- TWD 636.92M
- Total Debt (Recent Filing)
- TWD 17.92M
- Price to Earnings (P/E)
- ―
- Beta
- 0.52
- Next Earnings
- Mar 17, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
6492 FAQ
What was Senhwa Biosciences Inc’s price range in the past 12 months?
What is Senhwa Biosciences Inc’s market cap?
When is Senhwa Biosciences Inc’s upcoming earnings report date?
How were Senhwa Biosciences Inc’s earnings last quarter?
Is Senhwa Biosciences Inc overvalued?
Does Senhwa Biosciences Inc pay dividends?
What is Senhwa Biosciences Inc’s EPS estimate?
How many shares outstanding does Senhwa Biosciences Inc have?
What happened to Senhwa Biosciences Inc’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Senhwa Biosciences Inc?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Senhwa Biosciences Inc
Senhwa Biosciences, Inc., a pharmaceutical company established in 2012 and headquartered in New Taipei City, Taiwan, specializes in advancing novel drugs and targeted therapeutic agents. The firm is actively progressing several clinical programs. Its compound CX-5461 is undergoing various investigations, including a Phase I, open-label study assessing dose escalation, safety, pharmacokinetics, and pharmacodynamics of its intravenous administration in individuals with advanced blood cancers. CX-5461 is also in a Phase I trial for solid cancerous growths, as well as a Phase Ib expansion study focusing on solid tumors characterized by BRCA2 and/or PALB2 genetic mutations. Furthermore, CX-5461 is being evaluated in a Phase I trial alongside pidnarulex and talazoparib for patients battling metastatic castration-resistant prostate cancer. Beyond CX-5461, Senhwa is also developing several variations of CX-4945. CX-4945-CCA is participating in a Phase I/II clinical investigation, combined with gemcitabine, for treating cholangiocarcinoma. CX-4945-BCC is the subject of a Phase I, multi-center, open-label study, examining its safety and pharmacodynamic profile when administered orally twice daily to patients with advanced basal cell carcinoma. The company's CX-4945-MB compound is being explored in a Phase I/II and surgical study, led by a pediatric brain tumor consortium, for the management of recurrent SHH medulloblastoma. Lastly, CX-4945-AV06 is currently in a Phase II, double-blind, randomized, controlled study, designed to evaluate its safety and effectiveness in hospitalized adults afflicted with COVID-19.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Jason Huang
- Employees
- 15
- Website
- www.senhwabio.com
- Address
- No. 225, Peihsin Road, New Taipei City, CHA, 23143, TW
Senhwa Biosciences Inc (6492) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 4 | 14 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 0 | 0 | 12 |
